MA. ANTONIA
SALUD SALVIA
TEU
![Foto de MA. ANTONIA](/img/nophoto.png)
![Foto de Hospital Clinic Barcelona](/img/noimage_org.png)
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (12)
2023
-
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
Journal of the National Cancer Institute, Vol. 115, Núm. 12, pp. 1497-1505
2021
-
Clinical impact of presurgery circulating tumor DNA after total neoadjuvant treatment in locally advanced rectal cancer: A biomarker study from the GEMCAD 1402 trial
Clinical Cancer Research, Vol. 27, Núm. 10, pp. 2890-2898
2019
2018
-
Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients
Neoplasia (United States), Vol. 20, Núm. 7, pp. 678-686
2017
-
Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial
Tumor Biology, Vol. 39, Núm. 6
-
MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: Long-term results from the GEMCAD 0801 trial
Annals of Oncology, Vol. 28, Núm. 2, pp. 344-353
2015
-
Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: The phase II AVAXIRI study
BMC Cancer, Vol. 15, Núm. 1
-
Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: Long-term results of the Spanish GCR-3 phase II randomized trial
Annals of Oncology, Vol. 26, Núm. 8, pp. 1722-1728
-
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer
PLoS ONE, Vol. 10, Núm. 1
2014
-
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study
British Journal of Cancer, Vol. 111, Núm. 2, pp. 241-248
-
Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: The GEMCAD 0801 phase II multicenter trial
Oncologist, Vol. 19, Núm. 10, pp. 1042-1043
2013
-
Level of HER2 gene amplification predicts response and overall survival in her2-positive advanced gastric cancer treated with trastuzumab
Journal of Clinical Oncology, Vol. 31, Núm. 35, pp. 4445-4452